✦ LIBER ✦

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

✍ Scribed by Wu, Yi-Long; Fukuoka, Masahiro; Mok, Tony S.K.; Saijo, Nagahiro; Thongprasert, Sumitra; Yang, James C.H.; Chu, Da-Tong; Yang, Jin-Ji; Rukazenkov, Yuri

Book ID: 122839285
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 565 KB
Volume: 81
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.03.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

Phase III, randomized, open-label, first

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China

✍ Yi-Long WU; Da-Tong CHU; Baohui HAN; Xuyi LIU; Li ZHANG; Caicum ZHOU; Meilin LIA 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 815 KB

OP78 EGFR mutations based on circulating

OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB